Hydralazine
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Essential hypertension — oral therapy, alone or as an adjunct | Adults; chronic management | Add-on therapy after first-line agents | FDA Approved |
| Severe essential hypertension when oral therapy is not feasible or BP must be lowered urgently — parenteral therapy (IV/IM) | Adults in inpatient or emergency settings | Acute/short-term parenteral use | FDA Approved |
Hydralazine is one of the oldest available antihypertensives and remains a useful add-on agent in resistant hypertension and selected acute hypertensive scenarios. Per JNC 8 and current ACC/AHA hypertension guidance, it is not a first-line agent for essential hypertension because of dosing frequency, reflex tachycardia, sodium retention, and the risk of drug-induced lupus; it is added when first-line agents (thiazide, calcium channel blocker, ACEi/ARB) are insufficient or not tolerated. Its hemodynamic profile — predominantly arteriolar dilation with minimal venous effect — makes it most useful as an afterload reducer when combined with a beta-blocker (to control reflex tachycardia) and a diuretic (to control sodium and water retention). Reflex sympathetic activation also limits hydralazine monotherapy in coronary disease.
HFrEF — combination with isosorbide dinitrate (H-ISDN): Per the 2022 AHA/ACC/HFSA HF guideline, the fixed-dose combination of isosorbide dinitrate and hydralazine is a Class 1 recommendation in self-identified African-American patients with NYHA class III–IV HFrEF receiving optimal GDMT, based on the A-HeFT trial which showed a mortality benefit. It is also a Class 2a recommendation for patients of any race/ethnicity with current or prior symptomatic HFrEF who cannot tolerate ACEi/ARB/ARNI due to drug intolerance, hypotension, or renal insufficiency. Evidence quality: high (within the African-American HFrEF population).
Severe acute hypertension in pregnancy (preeclampsia / eclampsia / postpartum): IV hydralazine is recommended by ACOG (Practice Bulletin No. 222, incorporating Committee Opinion No. 767) as one of the first-line agents (alongside IV labetalol and oral immediate-release nifedipine) for sustained severe hypertension in pregnancy. Evidence quality: moderate.
Acute decompensated HF with severe hypertension: Sometimes used parenterally for afterload reduction when nitroprusside or nicardipine are unavailable or contraindicated. Evidence quality: low — based on hemodynamic rationale.
Dosing
Hydralazine dosing is structured by clinical scenario rather than by tablet strength. The drug has a short duration of action (approximately 2–4 hours orally), which mandates 2–4 doses per day for hypertension. For HFrEF, dosing is typically tied to the fixed-dose combination evaluated in A-HeFT.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Essential hypertension — initial titration (oral) | 10 mg PO four times daily × 2–4 days | 25 mg PO four times daily × 1 week, then 50 mg PO four times daily | 200 mg/day usual ceiling; up to 300 mg/day in resistant cases per the FDA label | Take with food at consistent times each day Pair with beta-blocker (controls reflex tachycardia) and a diuretic (controls fluid retention) |
| Hypertensive emergency / urgency in adults (parenteral, non-pregnant) | 10 mg slow IV; max initial dose 20 mg per StatPearls; FDA injection label cites 20–40 mg IV/IM | Repeat every 4–6 hours as needed | Per FDA injection label, certain patients (especially with marked renal damage) require lower doses | BP often falls within minutes; maximal effect at 10–80 min Avoid in suspected aortic dissection (reflex tachycardia worsens shear stress) |
| Severe acute hypertension in pregnancy (per ACOG) | 5–10 mg IV or IM | 5–10 mg IV every 20 minutes if BP remains ≥160/110 mmHg | Cumulative 20 mg per ACOG protocol; switch agent if not controlled | Higher and more frequent dosing is associated with maternal hypotension, headaches, and abnormal fetal tracings Continuous fetal monitoring during administration |
| HFrEF — adjunctive (with isosorbide dinitrate, per A-HeFT / fixed-dose BiDil) | Hydralazine 37.5 mg + ISDN 20 mg PO three times daily | Titrate to hydralazine 75 mg + ISDN 40 mg PO three times daily | Hydralazine 225 mg/day + ISDN 120 mg/day (at the maintenance dose taken three times daily) | BiDil fixed-dose product approved at the maintenance dose; same totals achievable with separate generic tablets Continue background ARNI/ACEi/ARB plus beta-blocker plus MRA plus SGLT2i unless contraindicated |
| HFrEF — patient intolerant to ACEi/ARB/ARNI (Class 2a, any race) | Hydralazine 25–50 mg + ISDN 20 mg PO three times daily | Hydralazine 75 mg + ISDN 40 mg PO three times daily as tolerated | Hydralazine 225 mg/day + ISDN 120 mg/day | Lower individual-component doses are reasonable when titrating outside the fixed-dose combination A nitrate-free interval is typical to limit nitrate tolerance |
| Missed dose (oral) | Take as soon as remembered if close to the scheduled time | — | — | If almost time for the next scheduled dose, skip the missed one and resume normal schedule Never double up |
Population-Specific Adjustments
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Slow acetylator phenotype (NAT2) | Use lower starting doses | Lower than usual maintenance | Lower ceiling; higher DILE risk | Slow acetylators have approximately twice the AUC of fast acetylators after a single oral dose, with higher steady-state plasma concentrations and a markedly higher risk of drug-induced lupus |
| Severe renal impairment (CrCl <10 mL/min) | Reduce starting dose or extend interval (e.g., q12–q24 h) | Individualize | Use the lowest effective dose | Reduced clearance and risk of accumulation; titrate slowly and monitor for hypotension |
| Hepatic impairment | Reduce dose | Individualize | Use the lowest effective dose | Hepatic acetylation is the primary metabolic pathway; impaired clearance increases exposure |
| Older adults (≥65 y) | Start at the low end of the range | Titrate slowly | As tolerated | Higher risk of orthostatic hypotension and falls; check standing BP |
| Pediatric oral (off-label, supported by clinical experience) | 0.75 mg/kg/day PO divided every 6–12 h | Titrate as needed up to 7.5 mg/kg/day | 7.5 mg/kg/day or 200 mg/day (whichever is less) | Per Mayo Clinic patient information and pediatric references; FDA label states safety/efficacy not established in controlled pediatric trials |
| Pediatric parenteral (hypertensive crisis) | 0.1–0.2 mg/kg/dose IV/IM every 4–6 hours PRN | May increase to 1.7–3.5 mg/kg/day in 4–6 divided doses (FDA injection label) | 20 mg per dose; 3.5 mg/kg/day | Clinical practice ranges per Medscape and major pediatric formularies; FDA label dose for severe acute hypertension is 1.7–3.5 mg/kg/day |
Chronic oral hydralazine for hypertension is rarely prescribed alone. Two predictable physiologic responses — reflex sympathetic activation (tachycardia, palpitations, anginal triggers) and renal sodium retention (edema, blunted antihypertensive effect) — are the reason. Pairing hydralazine with a beta-blocker (or non-dihydropyridine CCB) and a diuretic neutralizes both, and is the regimen that historically delivered sustained BP control. If a patient on hydralazine monotherapy is failing to respond, the answer is usually adding the missing partner drug rather than escalating the hydralazine dose.
Pharmacology
Mechanism of Action
Hydralazine produces direct relaxation of arteriolar smooth muscle, with little to no venous effect. The exact molecular mechanism remains incompletely characterized, but proposed actions include inhibition of inositol trisphosphate (IP3)-induced calcium release from the smooth muscle sarcoplasmic reticulum, interference with myosin light-chain phosphorylation, and contributions from prostaglandin- and nitric oxide-mediated pathways. The net hemodynamic effect is a fall in systemic vascular resistance and afterload.
The arteriolar selectivity has two clinically important consequences. First, hydralazine reduces afterload without preload reduction, which makes it complementary to nitrates (preload reducers) — the rationale behind the H-ISDN combination in HFrEF. Second, the abrupt drop in systemic resistance triggers a baroreceptor-mediated reflex sympathetic response with tachycardia, increased contractility, and renin–angiotensin–aldosterone activation. These compensatory responses can blunt the antihypertensive effect, precipitate angina in patients with coronary disease, and drive sodium and water retention. The standard countermeasures are concurrent therapy with a beta-blocker and a diuretic.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed orally; oral Tmax ~1 hour; bioavailability is highly variable and acetylator-dependent — slow acetylators have approximately twice the AUC of fast acetylators | Wide interpatient variability in exposure; titrate to clinical response rather than dose alone |
| Distribution | Wide tissue distribution; protein binding ~87%; crosses placenta and is excreted in breast milk | Extensive distribution; pregnancy and lactation considerations apply but the drug is widely used in obstetric care |
| Metabolism | Hepatic acetylation by N-acetyltransferase 2 (NAT2), with bimodal slow vs fast acetylator phenotypes; additional oxidation and conjugation | NAT2 polymorphism drives both response and toxicity: slow acetylators have higher exposure and substantially greater risk of drug-induced lupus |
| Elimination | Half-life approximately 3–7 hours (longer in renal impairment); <10% of an oral dose recovered in urine as parent drug; the remainder excreted as metabolites in urine and feces | Short half-life mandates 2–4× daily dosing; renal impairment prolongs duration and amplifies hypotension risk |
Side Effects
Most adverse reactions to hydralazine fall into two categories: (1) the predictable consequences of vasodilation and reflex sympathetic activation (headache, palpitations, tachycardia, flushing, hypotension, fluid retention), and (2) immune-mediated reactions from chronic exposure (drug-induced lupus, peripheral neuritis, rare blood dyscrasias, and rare ANCA-associated vasculitis). The FDA prescribing information explicitly notes that systematic frequency data have not been collected for most reactions, so the categorization below combines PI listings with published clinical observations.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | Very common precise rate not characterized in PI | Vasodilatory; usually most pronounced early in therapy and improves with continued use; treat with simple analgesia |
| Palpitations / reflex tachycardia | Very common | Predictable physiologic response; mitigated by concurrent beta-blocker |
| Anorexia, nausea, vomiting, diarrhea | Very common | Generally mild; taking with food may reduce GI symptoms |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Drug-induced lupus erythematosus (DILE) | ~5–10% cumulative; dose- and duration-dependent | Higher in slow acetylators, women, prolonged therapy (>6 months), and doses >200 mg/day; rates as high as 10–20% have been reported with cumulative exposure ≥400 mg/day. Most common features are arthralgia, fever, malaise, rash, and serositis. Most cases reverse after discontinuation. |
| Hypotension / dizziness | Common | Often orthostatic; counsel on slow positional changes; reduce diuretic dose if volume-depleted |
| Flushing, lacrimation, conjunctivitis, nasal congestion | Common | Mucosal vasodilation; usually self-limited and well-tolerated |
| Sodium and water retention / peripheral edema | Common | Counter-regulatory response to vasodilation; routinely managed by concomitant diuretic |
| Peripheral neuritis (paresthesia, numbness) | Uncommon to common | Antipyridoxine effect described in the FDA PI; pyridoxine (vitamin B6) supplementation usually reverses symptoms |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hydralazine-induced lupus syndrome with glomerulonephritis | Rare subset of DILE | Months to years; usually with prolonged or high-dose therapy | Discontinue hydralazine; rheumatology and nephrology consultation; long-term steroid therapy may be required per FDA PI |
| Angina or myocardial infarction (in coronary artery disease) | Uncommon overall; higher with monotherapy in CAD | Hours to days | Discontinue; standard ACS workup and management; avoid hydralazine monotherapy in known CAD |
| ANCA-positive vasculitis | Rare | Months to years | Discontinue; rheumatology referral; immunosuppression often required |
| Blood dyscrasias (hemolytic anemia, leukopenia, thrombocytopenia, agranulocytosis) | Rare | Weeks to months | Discontinue; CBC and reticulocyte count; hematology referral; usually reversible after withdrawal |
| Severe hypotension (especially parenteral; in volume-depleted or renally impaired patients) | Uncommon | Minutes (parenteral) to hours (oral) | Position supine; IV fluids; per FDA PI, vasopressors should be avoided if possible — if required, use with caution to avoid worsening tachyarrhythmia |
| Hypersensitivity reactions (rash, urticaria, anaphylaxis) | Rare | Any time | Discontinue permanently; standard hypersensitivity management; document allergy |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Drug-induced lupus / positive ANA with symptoms | Uncommon | Resolves in most patients within weeks of stopping; corticosteroids occasionally required |
| Headache and palpitations | Common reason | Often dose-related and may improve with concurrent beta-blocker |
| Worsening angina or new ischemic symptoms | Uncommon | Reflex tachycardia in CAD; switch to a non-stimulating antihypertensive class |
| Refractory fluid retention | Uncommon | Usually resolves with diuretic optimization rather than drug discontinuation |
Hydralazine-induced lupus presents most often as arthralgia or polyarthritis, low-grade fever, malaise, and a positive ANA, frequently with anti-histone antibodies; however, hydralazine is also an unusually common cause of drug-induced ANCA-associated vasculitis (often anti-MPO). Renal and CNS involvement, classic of idiopathic SLE, are less common. Risk factors include cumulative dose >200 mg/day, duration >6 months, female sex, and slow acetylator phenotype. Stop hydralazine, document the reaction in the chart, and avoid rechallenge. Serologies usually normalize over weeks to months; corticosteroids are reserved for severe organ involvement.
Drug Interactions
Most clinically important hydralazine interactions are pharmacodynamic — additive hypotension with other vasodilators, or antagonism by sodium-retaining agents. Hydralazine is not a major substrate of CYP enzymes; clearance is dominated by hepatic acetylation, so CYP-based interactions are not a typical concern.
Monitoring
Monitoring on hydralazine has two distinct rhythms: a short-term focus on hemodynamic tolerance during dose titration, and a long-term surveillance program for drug-induced autoimmune phenomena.
-
Blood Pressure & Heart Rate
Each visit during titration; periodically thereafter
Routine Check seated and standing BP. Watch for reflex tachycardia >90 bpm at rest, which often signals the need for a beta-blocker. For parenteral dosing, monitor BP frequently until stable. -
CBC & Antinuclear Antibody (ANA)
Baseline; periodically during prolonged therapy
Routine FDA PI specifies ANA and CBC determinations before therapy and periodically during prolonged use, even in asymptomatic patients. Repeat with new arthralgia, fever, chest pain, malaise, or other unexplained symptoms. A rising ANA without symptoms does not always require discontinuation, but warrants closer follow-up. -
Renal Function (creatinine, urinalysis)
Baseline; with routine HF/HTN labs
Routine Surveillance for hydralazine-associated glomerulonephritis (rare DILE complication) and for confirming safe dosing in declining renal function. New proteinuria or active urinary sediment merits prompt evaluation. -
Symptoms of DILE
Each visit; structured screen at 6, 12 months and annually
Routine Ask specifically about new joint pain or stiffness, low-grade fever, unusual fatigue, rashes, pleuritic chest pain, and serositis-type symptoms. Classic onset is after several months of therapy on doses ≥200 mg/day. -
Volume Status / Edema
Each visit
Routine Reflex sodium and water retention can blunt antihypertensive effect; check daily weights in HF patients and adjust diuretic before adding more antihypertensive load. -
Peripheral Sensory Symptoms
As needed
Trigger-based Numbness, tingling, or paresthesia suggest pyridoxine deficiency. Trial of vitamin B6 supplementation usually relieves symptoms; persistent neuritis warrants further workup. -
ECG / Cardiac Symptoms
As needed
Trigger-based Re-evaluate if new chest pain, worsening angina, or pronounced tachycardia. Caution in patients with known coronary disease or recent MI; reflex sympathetic activation can precipitate ischemia. -
Fetal Heart Rate (during obstetric use)
Continuous during parenteral dosing
Trigger-based Maternal hypotension after IV hydralazine has been associated with abnormal fetal tracings; intravenous fluid pre-loading and slow administration reduce this risk.
Contraindications & Cautions
The FDA prescribing information for hydralazine carries explicit warnings on two issues clinicians must internalize. First, hydralazine may produce a clinical syndrome resembling systemic lupus erythematosus, including glomerulonephritis; symptoms typically regress on discontinuation but residua may persist for years and long-term steroid therapy may be required. Second, myocardial stimulation produced by hydralazine can precipitate anginal attacks and ECG changes of myocardial ischemia; the drug has been associated with myocardial infarction and should be used with caution in patients with suspected coronary artery disease.
Complete blood counts and antinuclear antibody titer determinations should be obtained before initiating prolonged therapy and periodically during treatment, even in asymptomatic patients.
Absolute Contraindications
- Hypersensitivity to hydralazine
- Coronary artery disease — listed as a contraindication in the FDA parenteral (IV) label; the oral label warns against monotherapy in CAD because of reflex tachycardia
- Mitral valvular rheumatic heart disease — listed as a contraindication in the FDA parenteral label; afterload reduction can worsen hemodynamics in mitral stenosis
Relative Contraindications (Specialist Input Recommended)
- Suspected aortic dissection — reflex tachycardia and increased shear stress are detrimental; agents such as labetalol or esmolol (with nitroprusside if needed) are preferred
- Severe renal impairment (CrCl <10 mL/min) — reduced clearance and increased exposure; reduce dose or extend interval
- Pre-existing autoimmune disease (especially SLE) — risk of flare; use only if alternatives are unavailable and with rheumatology input
- Slow acetylator phenotype with prior reactions or family history of DILE — markedly elevated risk of drug-induced lupus
- Increased intracranial pressure (parenteral use) — abrupt BP lowering may worsen cerebral perfusion per the FDA injection label
Use with Caution
- Older adults — higher risk of orthostatic hypotension and falls; titrate slowly; check standing BP at each visit
- Pulmonary hypertension — reflex tachycardia and unpredictable hemodynamic effects; use only with specialist input
- Concurrent NSAID use — sodium retention may blunt antihypertensive effect; reassess if BP control is inadequate
- Patients with anginal symptoms — co-administration of a beta-blocker is essential to control reflex tachycardia
- Pregnancy — although IV hydralazine is widely used for severe acute hypertension in pregnancy, animal studies showed teratogenicity (cleft palate, craniofacial malformations) at exposures many times the maximum daily human dose; chronic oral use during pregnancy should be carefully weighed against alternatives such as labetalol or extended-release nifedipine
- Lactation — hydralazine is excreted in breast milk; clinical experience supports use during breastfeeding when needed, but observe the infant for unusual sedation, feeding difficulty, or hypotension
Hydralazine has a long history of use in obstetric care. ACOG includes IV hydralazine among first-line agents (with IV labetalol and oral immediate-release nifedipine) for severe acute hypertension in pregnancy and the postpartum period, with a recommended cumulative IV ceiling of 20 mg before switching agents. Animal teratogenicity has been observed at high doses, but extensive clinical experience in obstetric care does not demonstrate adverse fetal effects with therapeutic short-term use. Hydralazine is excreted in breast milk in small amounts and is generally considered compatible with breastfeeding; the infant should still be observed for unusual sedation, feeding difficulty, or hypotension.
Patient Counselling
Purpose of Therapy
Frame hydralazine as a blood pressure-lowering medicine that works by relaxing the arteries and reducing the workload on the heart. For patients with heart failure, the combination with a long-acting nitrate (isosorbide dinitrate) has additional benefits for symptoms and survival, especially in patients of African-American background or in those who cannot tolerate the standard heart failure medicines (ACE inhibitors, ARBs, or ARNI). The drug controls blood pressure rather than curing the underlying condition; benefits accrue with consistent daily use.
How to Take
Hydralazine is taken by mouth two to four times each day, depending on the prescribed dose. Take it at the same times every day, and try to take it with meals or a snack to reduce nausea. Patients should not change or stop their dose without instruction from the prescriber, as abrupt withdrawal can cause rebound rises in blood pressure. Most early side effects (headache, palpitations, mild dizziness) settle as the body adjusts.
Sources
- U.S. Food and Drug Administration. Apresoline (hydralazine hydrochloride) tablets — prescribing information. accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf FDA-approved oral hydralazine label including indication, dosing, adverse reaction listings, and the warnings on lupus-like syndrome and coronary stimulation.
- U.S. Food and Drug Administration. Hydralazine hydrochloride injection — prescribing information. accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf FDA-approved parenteral label specifying the contraindications (CAD, mitral valvular rheumatic heart disease) and the dosing for severe acute hypertension.
- U.S. Food and Drug Administration. BiDil (isosorbide dinitrate / hydralazine hydrochloride) — prescribing information. NDA 020727 (approval 2005). accessdata.fda.gov — NDA 020727 FDA approval record for the fixed-dose H-ISDN combination, with maintenance dosing of 37.5 mg/20 mg three times daily titrated up to 75 mg/40 mg three times daily.
- Taylor AL, Ziesche S, Yancy C, et al; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–2057. doi.org/10.1056/NEJMoa042934 A-HeFT — pivotal trial showing a mortality and hospitalization benefit of fixed-dose H-ISDN added to standard therapy in self-identified African-American patients with HFrEF.
- Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314(24):1547–1552. doi.org/10.1056/NEJM198606123142404 V-HeFT I — first trial demonstrating a survival benefit of H-ISDN over placebo in chronic heart failure.
- Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303–310. doi.org/10.1056/NEJM199108013250502 V-HeFT II — found enalapril superior to H-ISDN in overall survival but with similar mortality in self-identified Black participants, foundation for the racial subgroup hypothesis.
- Carson P, Ziesche S, Johnson G, Cohn JN; Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail. 1999;5(3):178–187. doi.org/10.1016/S1071-9164(99)90001-5 Post-hoc V-HeFT analysis identifying differential H-ISDN response in self-identified Black patients — the rationale that prompted A-HeFT.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032. doi.org/10.1161/CIR.0000000000001063 Class 1 recommendation for fixed-dose H-ISDN in self-identified African-American patients with NYHA III–IV HFrEF on optimal GDMT; Class 2a recommendation in any race intolerant to ACEi/ARB/ARNI.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13–e115. doi.org/10.1161/HYP.0000000000000065 U.S. hypertension guideline framework that places hydralazine as a secondary agent for resistant hypertension.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2020;135(6):e237–e260. doi.org/10.1097/AOG.0000000000003891 Practice Bulletin that incorporates ACOG Committee Opinion No. 767, designating IV hydralazine, IV labetalol, and oral immediate-release nifedipine as first-line for severe acute hypertension in pregnancy and the postpartum period (with a 20 mg cumulative IV hydralazine ceiling).
- Cole RT, Kalogeropoulos AP, Georgiopoulou VV, et al. Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation. 2011;123(21):2414–2422. doi.org/10.1161/CIRCULATIONAHA.110.012781 Comprehensive mechanistic review covering arteriolar vasodilation, nitric oxide modulation, attenuation of nitrate tolerance, and racial differences in response.
- Solhjoo M, Goyal A, Chauhan K. Drug-induced lupus erythematosus. StatPearls. Updated 2023. ncbi.nlm.nih.gov/books/NBK441889 Authoritative review of drug-induced lupus syndromes including hydralazine, with risk-factor profiles (slow acetylator, female sex, dose >200 mg/day, duration >6 months) and management.
- Herman LL, Bashir K. Hydralazine. StatPearls. Updated 2023. ncbi.nlm.nih.gov/books/NBK470296 Up-to-date overview of hydralazine pharmacology, dosing, monitoring, and toxicity with emphasis on acetylator phenotype variability.
- Ludden TM, McNay JL, Shepherd AM, Lin MS. Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet. 1982;7(3):185–205. doi.org/10.2165/00003088-198207030-00001 Detailed PK review covering bioavailability, acetylator phenotype effect on exposure, half-life, first-pass metabolism, and dosing implications.
- Reece PA, Cozamanis I, Zacest R. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype. J Pharmacokinet Biopharm. 1980;8(3):261–272. doi.org/10.1007/BF01059448 Foundational study showing that slow acetylators have approximately twice the AUC of fast acetylators after oral hydralazine — the empirical basis for acetylator-aware dosing.